Barclays Sees 21% Upside, Lifts Hims & Hers Price Target to $39
HIMS•Barclays raised its price target on Hims & Hers to $39 from $29, implying 21% upside and maintaining Overweight rating following its Novo Nordisk pact to sell Wegovy and Ozempic. Data show improving momentum since March, suggesting accelerating revenue and EBITDA growth in H2 2026 after breaking above $30 resistance.
1. Barclays Upgrade and Price Target Increase
Barclays raised its price target on Hims & Hers to $39 from $29 and maintained an Overweight rating, reflecting its bullish outlook on the telehealth company’s growth trajectory following recent strategic developments.
2. Novo Nordisk Partnership Details
On March 9, Hims & Hers began selling Novo Nordisk’s Wegovy and Ozempic drugs through its platform, marking a significant expansion of its weight-loss offering and driving early signs of increased customer engagement.
3. Growth Outlook and Technical Breakout
Proprietary and alternative data indicate accelerating demand since the collaboration announcement, with forecasts for meaningful revenue and EBITDA acceleration in H2 2026; shares trading above the $30 level could reinforce bullish sentiment.
